MX2020011089A - Compuestos antiproliferacion y usos de los mismos. - Google Patents
Compuestos antiproliferacion y usos de los mismos.Info
- Publication number
- MX2020011089A MX2020011089A MX2020011089A MX2020011089A MX2020011089A MX 2020011089 A MX2020011089 A MX 2020011089A MX 2020011089 A MX2020011089 A MX 2020011089A MX 2020011089 A MX2020011089 A MX 2020011089A MX 2020011089 A MX2020011089 A MX 2020011089A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- antiproliferation
- cancer
- formula
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Abstract
La presente invención proporciona compuestos de Fórmula I´, o sales farmacéuticamente aceptables de los mismos, composiciones farmacéuticas de los mismos, y métodos de uso de los mismos para el tratamiento de trastornos celulares proliferativos (por ejemplo, cáncer).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862661719P | 2018-04-24 | 2018-04-24 | |
PCT/US2019/028607 WO2019209759A1 (en) | 2018-04-24 | 2019-04-23 | Antiproliferation compounds and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020011089A true MX2020011089A (es) | 2020-11-06 |
Family
ID=66655429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020011089A MX2020011089A (es) | 2018-04-24 | 2019-04-23 | Compuestos antiproliferacion y usos de los mismos. |
Country Status (24)
Country | Link |
---|---|
US (3) | US10815225B2 (es) |
EP (2) | EP3784666B1 (es) |
JP (2) | JP7304892B2 (es) |
KR (1) | KR20210005151A (es) |
CN (1) | CN112236428A (es) |
AR (1) | AR114496A1 (es) |
AU (1) | AU2019261308B2 (es) |
BR (1) | BR112020020940A2 (es) |
CA (1) | CA3098335A1 (es) |
DK (1) | DK3784666T3 (es) |
ES (1) | ES2919572T3 (es) |
HR (1) | HRP20220710T1 (es) |
HU (1) | HUE058746T2 (es) |
IL (2) | IL301501A (es) |
LT (1) | LT3784666T (es) |
MX (1) | MX2020011089A (es) |
PL (1) | PL3784666T3 (es) |
PT (1) | PT3784666T (es) |
RS (1) | RS63281B1 (es) |
SG (1) | SG11202009500QA (es) |
SI (1) | SI3784666T1 (es) |
TW (1) | TWI813673B (es) |
WO (1) | WO2019209759A1 (es) |
ZA (1) | ZA202006071B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2919572T3 (es) | 2018-04-24 | 2022-07-27 | Merck Patent Gmbh | Compuestos antiproliferación y usos de los mismos |
WO2020010451A1 (en) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
WO2020236834A1 (en) * | 2019-05-20 | 2020-11-26 | Seshadri Raju | Modified z stents for iliac vein stenting |
AU2020406139A1 (en) | 2019-12-20 | 2022-06-30 | Bayer Aktiengesellschaft | Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof |
WO2024073502A1 (en) * | 2022-09-28 | 2024-04-04 | Accutar Biotechnology Inc. | Heterocyclic compounds as e3 ligase inhibitors |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
DE19840028A1 (de) | 1998-09-02 | 2000-03-09 | Max Planck Gesellschaft | Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen, und deren Verwendung |
DK1235830T3 (da) | 1999-12-10 | 2004-03-29 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
EP1389617B1 (en) | 2001-04-27 | 2007-01-03 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
ES2319894T3 (es) | 2002-08-14 | 2009-05-14 | Silence Therapeutics Aktiengesellschaft | Uso de la proteina quinasa-n-beta. |
WO2004089925A1 (en) | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
NZ543897A (en) | 2003-05-30 | 2009-04-30 | Gemin X Pharmaceuticals Canada | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
CN100577680C (zh) | 2003-07-03 | 2010-01-06 | 宾夕法尼亚大学理事会 | 对Syk激酶表达的抑制 |
DK1761540T3 (en) | 2004-05-13 | 2016-11-21 | Icos Corp | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase DELTA |
DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
CA2623768C (en) | 2005-10-07 | 2016-04-12 | Exelixis, Inc. | N-(3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
DK1951684T3 (en) | 2005-11-01 | 2016-10-24 | Targegen Inc | BIARYLMETAPYRIMIDIN kinase inhibitors |
MY162590A (en) | 2005-12-13 | 2017-06-30 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
AR060631A1 (es) | 2006-04-26 | 2008-07-02 | Piramed Ltd | Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k) |
EP2081435B1 (en) | 2006-09-22 | 2016-05-04 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
BRPI0808888B8 (pt) | 2007-03-12 | 2021-05-25 | Cytopia Res Pty Ltd | composto de fenil amino pirimidina para uso no tratamento de uma doença associada à quinase, processo para a preparação do composto, composição farmacêutica, e, implante |
WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
SI2288610T1 (sl) | 2008-03-11 | 2016-11-30 | Incyte Holdings Corporation | Derivati azetidina in ciklobutana kot inhibitorji jak |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
DE102008031517A1 (de) * | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
AR076014A1 (es) | 2009-04-02 | 2011-05-11 | Sanofi Aventis | Derivados de 3- (1,4) oxazepan -4-pirimidona |
CA2776724A1 (en) * | 2009-12-04 | 2011-06-09 | F. Hoffmann-La Roche Ag | Diphenyl azepine derivatives as monoamine reuptake inhibitors |
KR102062407B1 (ko) | 2010-12-09 | 2020-01-03 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도 |
CN107207482A (zh) | 2015-02-13 | 2017-09-26 | 默克专利股份公司 | 用于治疗癌症的嘧啶衍生物 |
ES2919572T3 (es) | 2018-04-24 | 2022-07-27 | Merck Patent Gmbh | Compuestos antiproliferación y usos de los mismos |
-
2019
- 2019-04-23 ES ES19726792T patent/ES2919572T3/es active Active
- 2019-04-23 AR ARP190101062A patent/AR114496A1/es unknown
- 2019-04-23 DK DK19726792.5T patent/DK3784666T3/da active
- 2019-04-23 WO PCT/US2019/028607 patent/WO2019209759A1/en unknown
- 2019-04-23 IL IL301501A patent/IL301501A/en unknown
- 2019-04-23 SG SG11202009500QA patent/SG11202009500QA/en unknown
- 2019-04-23 TW TW108114146A patent/TWI813673B/zh active
- 2019-04-23 AU AU2019261308A patent/AU2019261308B2/en active Active
- 2019-04-23 JP JP2020559394A patent/JP7304892B2/ja active Active
- 2019-04-23 US US16/391,419 patent/US10815225B2/en active Active
- 2019-04-23 BR BR112020020940-6A patent/BR112020020940A2/pt unknown
- 2019-04-23 SI SI201930251T patent/SI3784666T1/sl unknown
- 2019-04-23 CN CN201980036896.XA patent/CN112236428A/zh active Pending
- 2019-04-23 EP EP19726792.5A patent/EP3784666B1/en active Active
- 2019-04-23 PL PL19726792.5T patent/PL3784666T3/pl unknown
- 2019-04-23 CA CA3098335A patent/CA3098335A1/en active Pending
- 2019-04-23 MX MX2020011089A patent/MX2020011089A/es unknown
- 2019-04-23 KR KR1020207033873A patent/KR20210005151A/ko unknown
- 2019-04-23 PT PT197267925T patent/PT3784666T/pt unknown
- 2019-04-23 HU HUE19726792A patent/HUE058746T2/hu unknown
- 2019-04-23 RS RS20220537A patent/RS63281B1/sr unknown
- 2019-04-23 IL IL278142A patent/IL278142B2/en unknown
- 2019-04-23 EP EP22161962.0A patent/EP4043460A1/en active Pending
- 2019-04-23 HR HRP20220710TT patent/HRP20220710T1/hr unknown
- 2019-04-23 LT LTEPPCT/US2019/028607T patent/LT3784666T/lt unknown
-
2020
- 2020-08-27 US US17/004,109 patent/US11440907B1/en active Active
- 2020-09-30 ZA ZA2020/06071A patent/ZA202006071B/en unknown
-
2022
- 2022-09-07 US US17/930,352 patent/US20230150993A1/en active Pending
-
2023
- 2023-06-05 JP JP2023092450A patent/JP2023101824A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023004923A (es) | Compuestos heterociclicos como inmunomoduladores. | |
ZA202006071B (en) | Antiproliferation compounds and uses thereof | |
MX2021009246A (es) | Inmunomoduladores, composiciones y metodos de los mismos. | |
PH12021500014A1 (en) | Fused ring compounds | |
MX2019003887A (es) | Compuestos, dispositivos y usos de los mismos. | |
NZ765825A (en) | Benzamide compounds | |
EP3693369A3 (en) | Bromodomain inhibitors | |
MX2020006608A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
ZA202100485B (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
MX2020007947A (es) | Inhibidores de erbb/btk. | |
MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
MX2023005099A (es) | Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central. | |
PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
MX2020001719A (es) | Inhibidores macrocíclicos de mcl-1 y metodos de uso. | |
MX2020011868A (es) | Inhibidores de los receptores erbb. | |
JOP20190191A1 (ar) | وحدات شجرية علاجية | |
MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
NZ788133A (en) | Cd73 inhibitors | |
MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
MX2021007247A (es) | Derivados de rapamicina. | |
PH12019502652A1 (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
MX2020013729A (es) | Compuestos de cianotriazol y usos de los mismos. | |
PH12020500542A1 (en) | Dopamine-b-hydroxylase inhibitors |